Catalent Pharma Solutions

Catalent Pharma Solutions is an American contract development and manufacturing organization (CDMO) headquartered in Somerset, New Jersey, United States. Founded in 2007 as a spin-off from Cardinal Health, it provides drug formulation, manufacturing, and packaging services. The company's segments lude Biologics (cell/gene therapy development) and Pharma & Consumer Health (oral/injectable formulations). Catalent operates 50+ sites in 15 countries, supporting over 1,000 clients with end-to-end solutions from preclinical to commercialization. Its global supply chain involves API suppliers and equipment partners, complying with FDA, EMA, and ISO 13485 standards for quality and cGMP for biologics. Acquired by Novo Holdings in 2024 for $16.5 billion, it enhances capacity for peptide therapies. In fiscal year 2024, ending June 30, Catalent reported revenues of $4.38 billion, a 3% rease from 2023, driven by biologics growth despite COVID declines.